Somewhat Favorable News Coverage Somewhat Unlikely to Affect Anthera Pharmaceuticals (ANTH) Stock Price
Media headlines about Anthera Pharmaceuticals (NASDAQ:ANTH) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anthera Pharmaceuticals earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.4264845361488 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders – GlobeNewswire (press release) (globenewswire.com)
- Anthera Pharmaceuticals (ANTH) Raised to “Buy” at Zacks Investment Research (americanbankingnews.com)
- Exocrine Pancreatic Insufficiency – Pipeline Review, H2 2017: treatment to see significant rise in forecasted period (medgadget.com)
- Van Hulzen Asset Management Increased Comcast (CMCSA) Holding By $3.00 Million; Anthera Pharmaceuticals, Inc … – Hill Country Times (hillcountrytimes.com)
Shares of Anthera Pharmaceuticals (NASDAQ ANTH) remained flat at $$1.50 during trading hours on Tuesday. 317,462 shares of the stock traded hands, compared to its average volume of 327,415. The firm has a market capitalization of $20.71, a PE ratio of -0.28 and a beta of 2.71. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $6.24.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.32. During the same period in the previous year, the company earned ($4.85) EPS. equities research analysts forecast that Anthera Pharmaceuticals will post -3.09 earnings per share for the current year.
A number of research firms have recently commented on ANTH. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. Finally, Zacks Investment Research downgraded Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th.
ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/01/09/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-anthera-pharmaceuticals-anth-stock-price.html.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.